<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00854113</url>
  </required_header>
  <id_info>
    <org_study_id>THR-1474-C-328</org_study_id>
    <nct_id>NCT00854113</nct_id>
  </id_info>
  <brief_title>Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers</brief_title>
  <official_title>A Phase I , Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of EGT0001474 In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theracos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theracos</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated the safety, tolerability and pharmacokinetics of single or multiple
      doses of EGT0001474.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      EGT0001474 is an inhibitor of human sodium dependent glucose co-transporter II being
      developed for the treatment of Type II Diabetes mellitus.

      This is a singe center, Phase-1, double blinded,placebo controlled, dose escalation study of
      single and multiple ascending doses of EGT0001474 in healthy male and female subjects.

      In part-1, subjects were randomized to receive single doses of EGT0001474 at 2.5-150 mg or
      placebo in the ratio of 3:1. In part-2, subjects were randomized to receive 14 daily doses of
      EGT0001474 at 10, 50 and 150 mg or placebo in the ratio of 4:1. When the various doses were
      analysed, the maximum dose 150 mg was found to be tolerable. Although there was no serious
      adverse events, mild adverse events were observed.

      This study provided information on human safety, tolerability, PK and pharmacodynamic effects
      of EGT0001474.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Part-1 (Single dose) measured in 1 day and part 2 (multiple doses) measured in 14 days</time_frame>
    <description>Pharmacokinetics results. Cmax -Maximum plasma drug concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Part-1 (Single dose) measured in 1 day and part 2 (multiple doses) measured in 14 days</time_frame>
    <description>Pharmacokinetics results. Time to maximum plasma drug concentration (Tmax) was calculated for each groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-t</measure>
    <time_frame>Part-1 (Single dose) measured in 1 day and part 2 (multiple doses) measured in 14 days</time_frame>
    <description>Pharmacokinetics results. AUC 0-t - Are under plasma concentration-time curve from time 0 time t.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>Part-1 (Single dose) measured in 1 day and part 2 (multiple doses) measured in 14 days</time_frame>
    <description>Pharmacokinetics results.t 1/2 - apparent terminal half life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0 -24</measure>
    <time_frame>Part-1 (Single dose) measured in 1 day and part 2 (multiple doses) measured in 14 days</time_frame>
    <description>Pharmacokinetics results. Area under the plasma concentration-time curve from time 0 to 24 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Rate Constant.</measure>
    <time_frame>Part-1 (Single dose) measured in 1 day and part 2 (multiple doses) measured in 14 days</time_frame>
    <description>Pharmacokinetics results. Terminal rate constant was estimated by linear regression of logarithmic transformed concentration versus time data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F</measure>
    <time_frame>Part-1 (Single dose) measured in 1 day and part 2 (multiple doses) measured in 14 days</time_frame>
    <description>Pharmacokinetics results. Apparent oral clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VZ/F</measure>
    <time_frame>Part-1 (Single dose) measured in 1 day and part 2 (multiple doses) measured in 14 days</time_frame>
    <description>Pharmacokinetic results. Apparent volume of distribution</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Safety and Tolerability of EGT0001474 in Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>EGT0001474</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending doses of EGT0001474</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGT0001474</intervention_name>
    <description>Oral ascending doses given daily as capsules for up to 14 days</description>
    <arm_group_label>EGT0001474</arm_group_label>
    <other_name>Human SGLT2 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match EGT0001474</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Human SGLT2 inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female volunteers between the ages of 18 and 55 years inclusive.

          -  In good health.

          -  Female subjects must be surgically sterilized or postmenopausal.

          -  Body mass index (BMI) between 18 kg/m2 and 30 kg/m2 inclusive.

          -  Non-smoker.

          -  Negative drug and alcohol screens.

        Exclusion Criteria:

          -  Abnormal ECG

          -  Sitting blood pressure above 140/90 mmHg on 2 evaluations at least 10 minutes apart at
             screening

          -  Treatment with an investigational drug within 30 days or 7 half-lives, whichever is
             longer.

          -  Previous treatment with EGT0001474.

          -  History of drug abuse.

          -  Febrile illness within 5 days prior to the first dose of study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mason W. Freeman, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2009</study_first_submitted>
  <study_first_submitted_qc>February 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2009</study_first_posted>
  <results_first_submitted>October 25, 2010</results_first_submitted>
  <results_first_submitted_qc>July 18, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 12, 2011</results_first_posted>
  <last_update_submitted>July 18, 2011</last_update_submitted>
  <last_update_submitted_qc>July 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Albert Collinson Ph.D, President and CEO</name_title>
    <organization>Theracos</organization>
  </responsible_party>
  <keyword>Diabetes Mellitus Type 2</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Part 1 - Single Dose EGT0001474 2.5 mg</title>
          <description>Treatment group - received 2.5 mg single dose of EGT0001474</description>
        </group>
        <group group_id="P2">
          <title>Part 1 - Single Dose EGT0001474 5 mg</title>
          <description>Treatment group- received 5 mg single dose of EGT0001474</description>
        </group>
        <group group_id="P3">
          <title>Part 1 -Single Dose EGT0001474 10 mg</title>
          <description>Treatment group- received 10 mg single dose of EGT0001474</description>
        </group>
        <group group_id="P4">
          <title>Part 1 - Single Dose EGT0001474 25 mg</title>
          <description>Treatment group- received 25 mg single dose of EGT0001474</description>
        </group>
        <group group_id="P5">
          <title>Part 1 - Single Dose EGT0001474 75 mg</title>
          <description>Treatment group- received 75 mg single dose of EGT0001474</description>
        </group>
        <group group_id="P6">
          <title>Part 1 - Single Dose EGT0001474 150mg</title>
          <description>Treatment group- received 150 mg single dose of EGT0001474</description>
        </group>
        <group group_id="P7">
          <title>Part 1 - Single Dose Placebo</title>
          <description>Placebo group- received single dose of placebo capsule</description>
        </group>
        <group group_id="P8">
          <title>Part 2 - Mutiple Dose EGT0001474 10 mg</title>
          <description>Treatment group- received 14 daily doses of EGT0001474 at the dose of 10mg</description>
        </group>
        <group group_id="P9">
          <title>Part 2 - Multiple Dose EGT0001474 50 mg</title>
          <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 50mg</description>
        </group>
        <group group_id="P10">
          <title>Part 2 - Multiple Dose EGT0001474 150mg</title>
          <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 150mg</description>
        </group>
        <group group_id="P11">
          <title>Part 2 - Multiple Dose Placebo</title>
          <description>Placebo group- received placebo capsules for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1 - Single Dose EGT0001474 2.5 mg</title>
          <description>Treatment group - received 2.5 mg single dose of EGT0001474</description>
        </group>
        <group group_id="B2">
          <title>Part 1 - Single Dose EGT0001474 5 mg</title>
          <description>Treatment group- received 5 mg single dose of EGT0001474</description>
        </group>
        <group group_id="B3">
          <title>Part 1 -Single Dose EGT0001474 10 mg</title>
          <description>Treatment group- received 10 mg single dose of EGT0001474</description>
        </group>
        <group group_id="B4">
          <title>Part 1 - Single Dose EGT0001474 25 mg</title>
          <description>Treatment group- received 25 mg single dose of EGT0001474</description>
        </group>
        <group group_id="B5">
          <title>Part 1 - Single Dose EGT0001474 75 mg</title>
          <description>Treatment group- received 75 mg single dose of EGT0001474</description>
        </group>
        <group group_id="B6">
          <title>Part 1 - Single Dose EGT0001474 150mg</title>
          <description>Treatment group- received 150 mg single dose of EGT0001474</description>
        </group>
        <group group_id="B7">
          <title>Part 1 - Single Dose Placebo</title>
          <description>Placebo group- received single dose of placebo capsule</description>
        </group>
        <group group_id="B8">
          <title>Part 2 - Mutiple Dose EGT0001474 10 mg</title>
          <description>Treatment group- received 14 daily doses of EGT0001474 at the dose of 10mg</description>
        </group>
        <group group_id="B9">
          <title>Part 2 - Multiple Dose EGT0001474 50 mg</title>
          <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 50mg</description>
        </group>
        <group group_id="B10">
          <title>Part 2 - Multiple Dose EGT0001474 150mg</title>
          <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 150mg</description>
        </group>
        <group group_id="B11">
          <title>Part 2 - Multiple Dose Placebo</title>
          <description>Placebo group- received placebo capsules for 14 days</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="12"/>
            <count group_id="B8" value="8"/>
            <count group_id="B9" value="8"/>
            <count group_id="B10" value="8"/>
            <count group_id="B11" value="6"/>
            <count group_id="B12" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="29" upper_limit="55"/>
                    <measurement group_id="B2" value="26" lower_limit="18" upper_limit="31"/>
                    <measurement group_id="B3" value="25" lower_limit="19" upper_limit="40"/>
                    <measurement group_id="B4" value="32" lower_limit="18" upper_limit="55"/>
                    <measurement group_id="B5" value="29" lower_limit="23" upper_limit="35"/>
                    <measurement group_id="B6" value="35" lower_limit="23" upper_limit="55"/>
                    <measurement group_id="B7" value="33" lower_limit="19" upper_limit="53"/>
                    <measurement group_id="B8" value="30" lower_limit="20" upper_limit="44"/>
                    <measurement group_id="B9" value="35" lower_limit="21" upper_limit="49"/>
                    <measurement group_id="B10" value="22" lower_limit="18" upper_limit="28"/>
                    <measurement group_id="B11" value="26" lower_limit="22" upper_limit="32"/>
                    <measurement group_id="B12" value="32" lower_limit="18" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Pharmacokinetics results. Cmax -Maximum plasma drug concentration</description>
        <time_frame>Part-1 (Single dose) measured in 1 day and part 2 (multiple doses) measured in 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - Single Dose EGT0001474 2.5 mg</title>
            <description>Treatment group - received 2.5 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - Single Dose EGT0001474 5 mg</title>
            <description>Treatment group- received 5 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O3">
            <title>Part 1 -Single Dose EGT0001474 10 mg</title>
            <description>Treatment group- received 10 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - Single Dose EGT0001474 25 mg</title>
            <description>Treatment group- received 25 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - Single Dose EGT0001474 75 mg</title>
            <description>Treatment group- received 75 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - Single Dose EGT0001474 150mg</title>
            <description>Treatment group- received 150 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O7">
            <title>Part 1 - Single Dose Placebo</title>
            <description>Placebo group- received single dose of placebo capsule</description>
          </group>
          <group group_id="O8">
            <title>Part 2 - Mutiple Dose EGT0001474 10 mg</title>
            <description>Treatment group- received 14 daily doses of EGT0001474 at the dose of 10mg</description>
          </group>
          <group group_id="O9">
            <title>Part 2 - Multiple Dose EGT0001474 50 mg</title>
            <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 50mg</description>
          </group>
          <group group_id="O10">
            <title>Part 2 - Multiple Dose EGT0001474 150mg</title>
            <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 150mg</description>
          </group>
          <group group_id="O11">
            <title>Part 2 - Multiple Dose Placebo</title>
            <description>Placebo group- received placebo capsules for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Pharmacokinetics results. Cmax -Maximum plasma drug concentration</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="1.08"/>
                    <measurement group_id="O2" value="28" spread="10.2"/>
                    <measurement group_id="O3" value="90.7" spread="31.7"/>
                    <measurement group_id="O4" value="194" spread="53.3"/>
                    <measurement group_id="O5" value="537" spread="198"/>
                    <measurement group_id="O6" value="1183" spread="434"/>
                    <measurement group_id="O7" value="NA">Placebo did not receive EGT001474 drug.</measurement>
                    <measurement group_id="O8" value="85.7" spread="27.9"/>
                    <measurement group_id="O9" value="465" spread="126"/>
                    <measurement group_id="O10" value="1202" spread="345"/>
                    <measurement group_id="O11" value="NA">Placebo did not receive EGT001474 drug.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax</title>
        <description>Pharmacokinetics results. Time to maximum plasma drug concentration (Tmax) was calculated for each groups</description>
        <time_frame>Part-1 (Single dose) measured in 1 day and part 2 (multiple doses) measured in 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - Single Dose EGT0001474 2.5 mg</title>
            <description>Treatment group - received 2.5 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - Single Dose EGT0001474 5 mg</title>
            <description>Treatment group- received 5 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O3">
            <title>Part 1 -Single Dose EGT0001474 10 mg</title>
            <description>Treatment group- received 10 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - Single Dose EGT0001474 25 mg</title>
            <description>Treatment group- received 25 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - Single Dose EGT0001474 75 mg</title>
            <description>Treatment group- received 75 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - Single Dose EGT0001474 150mg</title>
            <description>Treatment group- received 150 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O7">
            <title>Part 1 - Single Dose Placebo</title>
            <description>Placebo group- received single dose of placebo capsule</description>
          </group>
          <group group_id="O8">
            <title>Part 2 - Mutiple Dose EGT0001474 10 mg</title>
            <description>Treatment group- received 14 daily doses of EGT0001474 at the dose of 10mg</description>
          </group>
          <group group_id="O9">
            <title>Part 2 - Multiple Dose EGT0001474 50 mg</title>
            <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 50mg</description>
          </group>
          <group group_id="O10">
            <title>Part 2 - Multiple Dose EGT0001474 150mg</title>
            <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 150mg</description>
          </group>
          <group group_id="O11">
            <title>Part 2 - Multiple Dose Placebo</title>
            <description>Placebo group- received placebo capsules for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Pharmacokinetics results. Time to maximum plasma drug concentration (Tmax) was calculated for each groups</description>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O2" value="2.01" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O3" value="2" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O4" value="1.51" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O5" value="1.5" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O6" value="1.5" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O7" value="NA">Placebo did not receive EGT001474 drug</measurement>
                    <measurement group_id="O8" value="2.01" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O9" value="1" lower_limit="1" upper_limit="6.05"/>
                    <measurement group_id="O10" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O11" value="NA">Placebo did not receive EGT001474 drug</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC 0-t</title>
        <description>Pharmacokinetics results. AUC 0-t - Are under plasma concentration-time curve from time 0 time t.</description>
        <time_frame>Part-1 (Single dose) measured in 1 day and part 2 (multiple doses) measured in 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - Single Dose EGT0001474 2.5 mg</title>
            <description>Treatment group - received 2.5 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - Single Dose EGT0001474 5 mg</title>
            <description>Treatment group- received 5 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O3">
            <title>Part 1 -Single Dose EGT0001474 10 mg</title>
            <description>Treatment group- received 10 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - Single Dose EGT0001474 25 mg</title>
            <description>Treatment group- received 25 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - Single Dose EGT0001474 75 mg</title>
            <description>Treatment group- received 75 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - Single Dose EGT0001474 150mg</title>
            <description>Treatment group- received 150 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O7">
            <title>Part 1 - Single Dose Placebo</title>
            <description>Placebo group- received single dose of placebo capsule</description>
          </group>
          <group group_id="O8">
            <title>Part 2 - Mutiple Dose EGT0001474 10 mg</title>
            <description>Treatment group- received 14 daily doses of EGT0001474 at the dose of 10mg</description>
          </group>
          <group group_id="O9">
            <title>Part 2 - Multiple Dose EGT0001474 50 mg</title>
            <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 50mg</description>
          </group>
          <group group_id="O10">
            <title>Part 2 - Multiple Dose EGT0001474 150mg</title>
            <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 150mg</description>
          </group>
          <group group_id="O11">
            <title>Part 2 - Multiple Dose Placebo</title>
            <description>Placebo group- received placebo capsules for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-t</title>
          <description>Pharmacokinetics results. AUC 0-t - Are under plasma concentration-time curve from time 0 time t.</description>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4" spread="13.9"/>
                    <measurement group_id="O2" value="126" spread="33.8"/>
                    <measurement group_id="O3" value="388" spread="108"/>
                    <measurement group_id="O4" value="1200" spread="320"/>
                    <measurement group_id="O5" value="2564" spread="607"/>
                    <measurement group_id="O6" value="6412" spread="1179"/>
                    <measurement group_id="O7" value="NA">Placebo did not receive EGT001474 drug.</measurement>
                    <measurement group_id="O8" value="432" spread="89.5"/>
                    <measurement group_id="O9" value="2146" spread="539"/>
                    <measurement group_id="O10" value="7733" spread="1957"/>
                    <measurement group_id="O11" value="NA">Placebo did not receive EGT001474 drug.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2</title>
        <description>Pharmacokinetics results.t 1/2 - apparent terminal half life</description>
        <time_frame>Part-1 (Single dose) measured in 1 day and part 2 (multiple doses) measured in 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - Single Dose EGT0001474 2.5 mg</title>
            <description>Treatment group - received 2.5 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - Single Dose EGT0001474 5 mg</title>
            <description>Treatment group- received 5 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O3">
            <title>Part 1 -Single Dose EGT0001474 10 mg</title>
            <description>Treatment group- received 10 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - Single Dose EGT0001474 25 mg</title>
            <description>Treatment group- received 25 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - Single Dose EGT0001474 75 mg</title>
            <description>Treatment group- received 75 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - Single Dose EGT0001474 150mg</title>
            <description>Treatment group- received 150 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O7">
            <title>Part 1 - Single Dose Placebo</title>
            <description>Placebo group- received single dose of placebo capsule</description>
          </group>
          <group group_id="O8">
            <title>Part 2 - Mutiple Dose EGT0001474 10 mg</title>
            <description>Treatment group- received 14 daily doses of EGT0001474 at the dose of 10mg</description>
          </group>
          <group group_id="O9">
            <title>Part 2 - Multiple Dose EGT0001474 50 mg</title>
            <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 50mg</description>
          </group>
          <group group_id="O10">
            <title>Part 2 - Multiple Dose EGT0001474 150mg</title>
            <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 150mg</description>
          </group>
          <group group_id="O11">
            <title>Part 2 - Multiple Dose Placebo</title>
            <description>Placebo group- received placebo capsules for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2</title>
          <description>Pharmacokinetics results.t 1/2 - apparent terminal half life</description>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.66" spread="0.559"/>
                    <measurement group_id="O2" value="4.19" spread="1.3"/>
                    <measurement group_id="O3" value="5.81" spread="1.38"/>
                    <measurement group_id="O4" value="9.71" spread="3.28"/>
                    <measurement group_id="O5" value="9.27" spread="1.60"/>
                    <measurement group_id="O6" value="11.4" spread="2.49"/>
                    <measurement group_id="O7" value="NA">Placebo did not receive EGT001474 drug.</measurement>
                    <measurement group_id="O8" value="9.03" spread="1.44"/>
                    <measurement group_id="O9" value="9.02" spread="2.38"/>
                    <measurement group_id="O10" value="10.3" spread="1.98"/>
                    <measurement group_id="O11" value="NA">Placebo did not receive EGT001474 drug.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC 0 -24</title>
        <description>Pharmacokinetics results. Area under the plasma concentration-time curve from time 0 to 24 hours post-dose.</description>
        <time_frame>Part-1 (Single dose) measured in 1 day and part 2 (multiple doses) measured in 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - Single Dose EGT0001474 2.5 mg</title>
            <description>Treatment group - received 2.5 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - Single Dose EGT0001474 5 mg</title>
            <description>Treatment group- received 5 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O3">
            <title>Part 1 -Single Dose EGT0001474 10 mg</title>
            <description>Treatment group- received 10 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - Single Dose EGT0001474 25 mg</title>
            <description>Treatment group- received 25 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - Single Dose EGT0001474 75 mg</title>
            <description>Treatment group- received 75 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - Single Dose EGT0001474 150mg</title>
            <description>Treatment group- received 150 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O7">
            <title>Part 1 - Single Dose Placebo</title>
            <description>Placebo group- received single dose of placebo capsule</description>
          </group>
          <group group_id="O8">
            <title>Part 2 - Mutiple Dose EGT0001474 10 mg</title>
            <description>Treatment group- received 14 daily doses of EGT0001474 at the dose of 10mg</description>
          </group>
          <group group_id="O9">
            <title>Part 2 - Multiple Dose EGT0001474 50 mg</title>
            <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 50mg</description>
          </group>
          <group group_id="O10">
            <title>Part 2 - Multiple Dose EGT0001474 150mg</title>
            <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 150mg</description>
          </group>
          <group group_id="O11">
            <title>Part 2 - Multiple Dose Placebo</title>
            <description>Placebo group- received placebo capsules for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0 -24</title>
          <description>Pharmacokinetics results. Area under the plasma concentration-time curve from time 0 to 24 hours post-dose.</description>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.6" spread="9.67"/>
                    <measurement group_id="O2" value="145" spread="34.4"/>
                    <measurement group_id="O3" value="392" spread="99.8"/>
                    <measurement group_id="O4" value="1121" spread="264"/>
                    <measurement group_id="O5" value="2383" spread="527"/>
                    <measurement group_id="O6" value="5828" spread="1080"/>
                    <measurement group_id="O7" value="NA">Placebo did not receive EGT001474 drug.</measurement>
                    <measurement group_id="O8" value="412" spread="73.8"/>
                    <measurement group_id="O9" value="1983" spread="443"/>
                    <measurement group_id="O10" value="6939" spread="1675"/>
                    <measurement group_id="O11" value="NA">Placebo did not receive EGT001474 drug.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Rate Constant.</title>
        <description>Pharmacokinetics results. Terminal rate constant was estimated by linear regression of logarithmic transformed concentration versus time data</description>
        <time_frame>Part-1 (Single dose) measured in 1 day and part 2 (multiple doses) measured in 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - Single Dose EGT0001474 2.5 mg</title>
            <description>Treatment group - received 2.5 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - Single Dose EGT0001474 5 mg</title>
            <description>Treatment group- received 5 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O3">
            <title>Part 1 -Single Dose EGT0001474 10 mg</title>
            <description>Treatment group- received 10 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - Single Dose EGT0001474 25 mg</title>
            <description>Treatment group- received 25 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - Single Dose EGT0001474 75 mg</title>
            <description>Treatment group- received 75 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - Single Dose EGT0001474 150mg</title>
            <description>Treatment group- received 150 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O7">
            <title>Part 1 - Single Dose Placebo</title>
            <description>Placebo group- received single dose of placebo capsule</description>
          </group>
          <group group_id="O8">
            <title>Part 2 - Mutiple Dose EGT0001474 10 mg</title>
            <description>Treatment group- received 14 daily doses of EGT0001474 at the dose of 10mg</description>
          </group>
          <group group_id="O9">
            <title>Part 2 - Multiple Dose EGT0001474 50 mg</title>
            <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 50mg</description>
          </group>
          <group group_id="O10">
            <title>Part 2 - Multiple Dose EGT0001474 150mg</title>
            <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 150mg</description>
          </group>
          <group group_id="O11">
            <title>Part 2 - Multiple Dose Placebo</title>
            <description>Placebo group- received placebo capsules for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Rate Constant.</title>
          <description>Pharmacokinetics results. Terminal rate constant was estimated by linear regression of logarithmic transformed concentration versus time data</description>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.193" spread="0.0314"/>
                    <measurement group_id="O2" value="0.177" spread="0.0456"/>
                    <measurement group_id="O3" value="0.126" spread="0.0373"/>
                    <measurement group_id="O4" value="0.0799" spread="0.0308"/>
                    <measurement group_id="O5" value="0.0765" spread="0.0117"/>
                    <measurement group_id="O6" value="0.0637" spread="0.0158"/>
                    <measurement group_id="O7" value="NA">Placebo did not receive EGT001474 drug.</measurement>
                    <measurement group_id="O8" value="0.0783" spread="0.0117"/>
                    <measurement group_id="O9" value="0.0818" spread="0.023"/>
                    <measurement group_id="O10" value="0.0697" spread="0.0143"/>
                    <measurement group_id="O11" value="NA">Placebo did not receive EGT001474 drug.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CL/F</title>
        <description>Pharmacokinetics results. Apparent oral clearance</description>
        <time_frame>Part-1 (Single dose) measured in 1 day and part 2 (multiple doses) measured in 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - Single Dose EGT0001474 2.5 mg</title>
            <description>Treatment group - received 2.5 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - Single Dose EGT0001474 5 mg</title>
            <description>Treatment group- received 5 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O3">
            <title>Part 1 -Single Dose EGT0001474 10 mg</title>
            <description>Treatment group- received 10 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - Single Dose EGT0001474 25 mg</title>
            <description>Treatment group- received 25 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - Single Dose EGT0001474 75 mg</title>
            <description>Treatment group- received 75 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - Single Dose EGT0001474 150mg</title>
            <description>Treatment group- received 150 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O7">
            <title>Part 1 - Single Dose Placebo</title>
            <description>Placebo group- received single dose of placebo capsule</description>
          </group>
          <group group_id="O8">
            <title>Part 2 - Mutiple Dose EGT0001474 10 mg</title>
            <description>Treatment group- received 14 daily doses of EGT0001474 at the dose of 10mg</description>
          </group>
          <group group_id="O9">
            <title>Part 2 - Multiple Dose EGT0001474 50 mg</title>
            <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 50mg</description>
          </group>
          <group group_id="O10">
            <title>Part 2 - Multiple Dose EGT0001474 150mg</title>
            <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 150mg</description>
          </group>
          <group group_id="O11">
            <title>Part 2 - Multiple Dose Placebo</title>
            <description>Placebo group- received placebo capsules for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F</title>
          <description>Pharmacokinetics results. Apparent oral clearance</description>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" spread="2.89"/>
                    <measurement group_id="O2" value="35.3" spread="8.24"/>
                    <measurement group_id="O3" value="25.9" spread="7.59"/>
                    <measurement group_id="O4" value="21.2" spread="5.18"/>
                    <measurement group_id="O5" value="30.1" spread="8.51"/>
                    <measurement group_id="O6" value="23.1" spread="3.67"/>
                    <measurement group_id="O7" value="NA">Placebo did not receive EGT001474 drug.</measurement>
                    <measurement group_id="O8" value="24.9" spread="4.45"/>
                    <measurement group_id="O9" value="26.4" spread="6.49"/>
                    <measurement group_id="O10" value="22.6" spread="4.67"/>
                    <measurement group_id="O11" value="NA">Placebo did not receive EGT001474 drug.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>VZ/F</title>
        <description>Pharmacokinetic results. Apparent volume of distribution</description>
        <time_frame>Part-1 (Single dose) measured in 1 day and part 2 (multiple doses) measured in 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - Single Dose EGT0001474 2.5 mg</title>
            <description>Treatment group - received 2.5 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - Single Dose EGT0001474 5 mg</title>
            <description>Treatment group- received 5 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O3">
            <title>Part 1 -Single Dose EGT0001474 10 mg</title>
            <description>Treatment group- received 10 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - Single Dose EGT0001474 25 mg</title>
            <description>Treatment group- received 25 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - Single Dose EGT0001474 75 mg</title>
            <description>Treatment group- received 75 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - Single Dose EGT0001474 150mg</title>
            <description>Treatment group- received 150 mg single dose of EGT0001474</description>
          </group>
          <group group_id="O7">
            <title>Part 1 - Single Dose Placebo</title>
            <description>Placebo group- received single dose of placebo capsule</description>
          </group>
          <group group_id="O8">
            <title>Part 2 - Mutiple Dose EGT0001474 10 mg</title>
            <description>Treatment group- received 14 daily doses of EGT0001474 at the dose of 10mg</description>
          </group>
          <group group_id="O9">
            <title>Part 2 - Multiple Dose EGT0001474 50 mg</title>
            <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 50mg</description>
          </group>
          <group group_id="O10">
            <title>Part 2 - Multiple Dose EGT0001474 150mg</title>
            <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 150mg</description>
          </group>
          <group group_id="O11">
            <title>Part 2 - Multiple Dose Placebo</title>
            <description>Placebo group- received placebo capsules for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>VZ/F</title>
          <description>Pharmacokinetic results. Apparent volume of distribution</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154" spread="37.1"/>
                    <measurement group_id="O2" value="222" spread="121"/>
                    <measurement group_id="O3" value="208" spread="49.5"/>
                    <measurement group_id="O4" value="287" spread="105"/>
                    <measurement group_id="O5" value="398" spread="109"/>
                    <measurement group_id="O6" value="385" spread="121"/>
                    <measurement group_id="O7" value="NA">Placebo did not receive EGT001474 drug.</measurement>
                    <measurement group_id="O8" value="319" spread="39.3"/>
                    <measurement group_id="O9" value="327" spread="54.2"/>
                    <measurement group_id="O10" value="333" spread="84.2"/>
                    <measurement group_id="O11" value="NA">Placebo did not receive EGT001474 drug.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Part 1 - Single Dose EGT0001474 2.5 mg</title>
          <description>Treatment group - received 2.5 mg single dose of EGT0001474</description>
        </group>
        <group group_id="E2">
          <title>Part 1 - Single Dose EGT0001474 5 mg</title>
          <description>Treatment group- received 5 mg single dose of EGT0001474</description>
        </group>
        <group group_id="E3">
          <title>Part 1 -Single Dose EGT0001474 10 mg</title>
          <description>Treatment group- received 10 mg single dose of EGT0001474</description>
        </group>
        <group group_id="E4">
          <title>Part 1 - Single Dose EGT0001474 25 mg</title>
          <description>Treatment group- received 25 mg single dose of EGT0001474</description>
        </group>
        <group group_id="E5">
          <title>Part 1 - Single Dose EGT0001474 75 mg</title>
          <description>Treatment group- received 75 mg single dose of EGT0001474</description>
        </group>
        <group group_id="E6">
          <title>Part 1 - Single Dose EGT0001474 150mg</title>
          <description>Treatment group- received 150 mg single dose of EGT0001474</description>
        </group>
        <group group_id="E7">
          <title>Part 1 - Single Dose Placebo</title>
          <description>Placebo group- received single dose of placebo capsule</description>
        </group>
        <group group_id="E8">
          <title>Part 2 - Mutiple Dose EGT0001474 10 mg</title>
          <description>Treatment group- received 14 daily doses of EGT0001474 at the dose of 10mg</description>
        </group>
        <group group_id="E9">
          <title>Part 2 - Multiple Dose EGT0001474 50 mg</title>
          <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 50mg</description>
        </group>
        <group group_id="E10">
          <title>Part 2 - Multiple Dose EGT0001474 150mg</title>
          <description>Treatment group-received 14 daily doses of EGT0001474 at the dose of 150mg</description>
        </group>
        <group group_id="E11">
          <title>Part 2 - Multiple Dose Placebo</title>
          <description>Placebo group- received placebo capsules for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tongue Ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Erythema</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>General disorders and administrative site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Application Site Irritation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>General disorders and administrative site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>General disorders and administrative site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>General disorders and administrative site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>General disorders and administrative site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>General disorders and administrative site conditions</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tooth Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle Tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Head Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharangeal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yuan-Di Halvorsen</name_or_title>
      <organization>Theracos</organization>
      <phone>617-726-4236</phone>
      <email>yhalvorsen@ccib.mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

